It has been reported that following the administration of melphalan (high-dose) and autologous stem cell transplantation (ASCT), anti-CD19-CAR-T cell (CTL019) has emerged well-tolerated complete response in refractory MM cases [35]. Here, CD19 is linked to Miyoshi myopathy.